Deutsche Bank Keeps 'Buy' on Tenet Healthcare

Analyst Scott Estes says with $16 billion in revenue, any negative outcome from fraud allegations is likely to be limited

Deutsche Bank maintains its buy rating on Tenet Healthcare (THC )

To continue reading this article you must be a Bloomberg Professional Service Subscriber.